Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004058 · ClinicalTrials.gov registry record · Phase 1
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
A Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00004058 is a Phase 1 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey.
The verdict
NCT00004058, a Phase 1 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorder that has not responded to previous treatment.
Interventions
- DRUG tetradecanoylphorbol acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004058
The ClinicalTrials.gov registry entry for NCT00004058 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tetradecanoylphorbol acetate is the first listed.
NCT00004058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004058 about?
NCT00004058 is a clinical study titled "12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorde...
What is the current status of trial NCT00004058?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-12. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00004058?
The interventions under investigation include: tetradecanoylphorbol acetate (DRUG).
Who is sponsoring clinical trial NCT00004058?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.